Heterocyclic inhibitors of glycine transporter 2

Details Heterocyclic inhibitors of glycine transporter 2 Heterocyclic inhibitors of glycine transporter 2

2005-05-17

2005-05-17

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S256000, C514S262100, C514S263200, C514S307000, C514S342000, C514S363000

Reexamination Certificate

active

06894054

ABSTRACT:
Compounds, compositions, and methods for inhibiting the glycine transporter2and for inhibiting glycine transporter mediated neuronal activity. These compounds are particularly useful for treating diseases of the nerve and muscle, including psychoses, pain, epilepsy, neurodegenerative diseases, stroke, head trauma, multiple sclerosis and the like, and of muscle disorders, including diseases or conditions associated with increased muscle contraction, such as spasticity and myoclonus. In addition, the compounds may be used to discover other agents with improved activity in assays in which the compounds of the invention are active.

REFERENCES:
patent: 4097669 (1978-06-01), Reisdorff et al.
patent: 4325959 (1982-04-01), Matthews
patent: 5587293 (1996-12-01), Kauvar et al.
patent: 5668159 (1997-09-01), Jin
patent: 5670526 (1997-09-01), Dodd et al.
patent: 5756348 (1998-05-01), Smith et al.
patent: 5968823 (1999-10-01), Borden et al.
patent: 6008015 (1999-12-01), Albert et al.
patent: 6127131 (2000-10-01), Smith et al.
patent: 30 31 191 (1981-03-01), None
patent: 37 17 865 (1988-12-01), None
patent: 0 214 732 (1987-03-01), None
patent: 0 276 793 (1988-01-01), None
patent: 0 409 332 (1991-01-01), None
patent: 0 554 107 (1993-08-01), None
patent: 2 263 635 (1993-08-01), None
patent: 11-043485 (1989-06-01), None
patent: 2-129173 (1990-05-01), None
patent: 7-005646 (1995-01-01), None
patent: 9-114055 (1997-05-01), None
patent: 10-036357 (1998-02-01), None
patent: WO 9111909 (1991-08-01), None
patent: WO 9513268 (1995-05-01), None
patent: WO 9745115 (1997-12-01), None
patent: WO 9745423 (1997-12-01), None
patent: WO 9830561 (1998-07-01), None
patent: WO 9944596 (1999-09-01), None
patent: WO 9945011 (1999-09-01), None
patent: WO 0157024 (2001-08-01), None
patent: WO 0187855 (2001-11-01), None
Gomeza et al. Glycine transporter isoforms in the mammalian central nervous sytem: Structrues, functions and therapeutic promises, Current Opinion in Drug Discovery and Development 6(5):675-682, 2003.*
Hazzaa et al., Synthesis and biological evalution of 3-quinolyl-5-mercapto-1,2,4-triazoles,Sci Pharm, 46(4), 298-306 (1978).
Gulerman et al., “Evaluation of antimycobacterial and anticonvulsant activities of new 1-(4-fluoro-benzoyl)-4-substituted-2,4-dihydro-3H-1,2,4-triazole-3-thione derivatives”,II Farmaco, 52(11), 691-695 (1997).
Chem Abs, 128(3), 22862 (1998); Abstract of Habib et al., “Synthesis and antimicrobial testing of novel oxadiazolylbenzimidazole dericatives”,Pharmazie, 52(10), 746-749 (1997).
Biosis Database, Abstract No. PREV200100076408 (2000); Abstract of Lechner et al., “Novel glycine transporter 2 inhibitors are analgesic in a rat model of inflammatory pain”,Soc Neurosci Abs, 26(1-2), Abstract 150.18 (2000).

Affiliated with

Also associated with

Rating

Heterocyclic inhibitors of glycine transporter 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic inhibitors of glycine transporter 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of glycine transporter 2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3370196